Characteristics of the participants by profile groups
| Variable | All n=1996 | Group 1 n=781 | Group 2 n=611 | Group 3 n=604 | P value |
| Age, y | 62.7±10.9 | 60.9±10.9 | 63.7±10.7* | 63.8±10.6* | <0.001 |
| Female, n (%) | 656 (32.9) | 258 (33.0) | 203 (33.2) | 195 (32.3) | 0.93 |
| Smoker, n (%) | 860 (43.1) | 350 (44.8) | 252 (41.2) | 258 (42.7) | 0.39 |
| Drinker, n (%) | 745 (37.4) | 314 (40.2) | 212 (34.7)† | 219 (36.2) | 0.09 |
| NIHSS, median (IQR) | 2 (1 to 4) | 2 (1 to 4) | 2 (1 to 4) | 2 (1 to 5) | 0.48 |
| IS, n (%) | 1761 (88.2) | 686 (87.8) | 532 (87.1) | 543 (89.9) | 0.28 |
| Medical history, n (%) | |||||
| Stroke | 469 (23.5) | 167 (21.4) | 146 (23.9) | 156 (25.8) | 0.15 |
| Hypertension | 1403 (70.3) | 545 (69.8) | 420 (68.7) | 438 (72.5) | 0.33 |
| Diabetes mellitus | 433 (21.7) | 158 (20.2) | 125 (20.5) | 150 (24.8) | 0.08 |
| Dyslipidaemia | 209 (10.5) | 98 (12.6) | 69 (11.3) | 42 (6.95) * | 0.01 |
| CHD | 214 (10.7) | 62 (7.9) | 81 (13.3)* | 71 (11.8)* | 0.01 |
| Atrial fibrillation | 52 (2.6) | 14 (1.97) | 18 (2.95) | 20 (3.31) | 0.17 |
| History of Medication, n (%) | |||||
| Antiplatelet therapy | 409 (20.5) | 124 (20.6) | 127 (20.8) | 158 (20.3) | 0.97 |
| Statin therapy | 201 (10.1) | 77 (9.8) | 63 (10.31) | 61 (10.1) | 0.96 |
| Antihypertensive | 1087 (54.5) | 402 (51.6) | 334 (54.7) | 351 (58.2) | 0.05 |
| Anticoagulant | 3 (0.6) | 3 (0.4) | 4 (0.7) | 4 (0.7) | 0.75 |
| Medication at discharge, n (%) | |||||
| Antiplatelet therapy | 1868 (93.6) | 732 (93.7) | 565 (92.5) | 571 (94.5) | 0.33 |
| Statin therapy | 1670 (83.7) | 659 (84.4) | 500 (81.8) | 511 (84.6) | 0.02 |
| Antihypertensive | 1334 (66.8) | 511 (65.4) | 392 (64.2) | 431 (71.4)† | 0.34 |
| Anticoagulant | 20 (1.0) | 7 (0.9) | 7 (1.2) | 6 (1.0) | 0.90 |
*p<0.01 for comparison with group 1.
†P<0.05.
CHD, coronary heart disease; IS, ischemicischaemic stroke; NIHSS, National Institute of Health Stroke Scale.